Tech Company Inital Public Offerings
KaloBios Pharmaceuticals IPO
KaloBios Pharmaceuticals was purchased by . KaloBios Pharmaceuticals shares became public on 1/31/2013.
Transaction Overview
Company Name
Announced On
1/31/2013
Transaction Type
IPO
Amount
$70,400,000
Proceeds Purpose
Proceeds purposes are on file with company statements at the SEC.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1000 Marina Blvd. 250
Brisbane, CA 94005
USA
Brisbane, CA 94005
USA
Phone
Website
Email Address
Overview
KaloBios (NASDAQ: KBIO) is a vertically integrated therapeutic antibody company using its proprietary antibody engineering, humaneering and expression technologies for the development of a pipeline of antibody therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Cameron Durrant
Browse more venture capital transactions:
Prev: 1/31/2013: Internet Time Machine Project venture capital transaction
Next: 2/1/2013: Aratana Therapeutics venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs